Esperion(US:ESPR) Globenewswire·2025-11-10 13:00Core Insights - Esperion presented two post hoc analyses from the CLEAR Outcomes trial, highlighting the efficacy of bempedoic acid in reducing major adverse cardiovascular events (MACE-4) and venous thromboembolism (VTE) in patients not receiving other lipid-lowering therapies [1][2][3] Group 1: Efficacy of Bempedoic Acid - Bempedoic acid alone reduced MACE-4 by 14% compared to placebo in approximately 8,200 patients not on background lipid-lowering therapies [1][8] - The drug lowered LDL cholesterol by 20.6% at 6 months [8] - Patients treated with bempedoic acid were 42% less likely to experience VTE events compared to those on placebo, with a 44% reduction in deep venous thrombosis and a 39% reduction in pulmonary embolism [1][8] Group 2: Clinical Significance - The analyses reinforce the clinical value of NEXLETOL as a foundational therapy for cardiovascular risk reduction, especially for patients intolerant to statins [3] - The consistency of benefits from bempedoic acid monotherapy in lowering LDL-C and reducing MACE underscores its potential in preventive cardiology [3] Group 3: Presentation and Context - The data were presented at the 2025 American Heart Association Scientific Sessions, a significant forum in cardiovascular medicine [1][3] - Over half (59%) of the 13,970 participants in the CLEAR Outcomes trial were not receiving any background lipid-lowering therapy during the study [8]